TF and cancer: In this regard, we were able to simultaneously target angiogenic VECs and cancer cells by targeting receptor TF using its natural ligand fVII-conjugated SnCe6 or verteporfin for the treatment of breast cancer in preclinical studies (Hu et al, 2010a, 2010b).